Revenue growth accelerates sharply
Revenue increased 98.6% year over year to $37.6 million, while cost of revenue rose only 73.8%, driving a 113.1% increase in gross profit.
Eton Pharmaceuticals, Inc. is expected to release its Q3 2026 10-Q filing on November 9, 2026. Last quarter: ETON's Q2 FY2026 revenue nearly doubled while the company swung from a net loss to a substantial net profit on sharply improved margins, though rising current liabilities and steep R&D cuts present questions for sustainability.
EPS Estimate
$0.21
Revenue Estimate
$32.42M
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the ETON page.
Drawn from management commentary in the Q2 2026 10-Q:
Revenue increased 98.6% year over year to $37.6 million, while cost of revenue rose only 73.8%, driving a 113.1% increase in gross profit.
Operating income swung from a loss of $1.5 million to a profit of $12.8 million, and net income turned from a loss of $2.6 million to a profit of $11.6 million.
Research and development expense fell 73.2% to $0.99 million, materially supporting the expansion in operating margin.
Revenue
$37.59M
+98.59% YoY
EPS (Diluted)
$0.35
+450.00% YoY
Gross Margin
67.6%
+4.6 pts YoY
Operating Income
$12.79M
+967.39% YoY
Add ETON to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.